DOM FIGURE 3 Chronic effects of AZD1656 on blood glucose, liver triglycerides and glucokinase activity.
A-D: C57BL/6 mice were treated for 1-wk without or with AZD1656 (at 0.3, 1, 3 and 9 mg/kg body wt): A, Blood glucose; B, plasma insulin at the times indicated; C, Liver mRNA levels; D, liver glucokinase activity. Means ± SEM for n=6, * P< 0.05 vs vehicle.
E-L: C57BL/6 mice were treated for 4-wk or 8-wk without (0) or with AZD1656 (1 or 3mg/kg body wt): E, blood glucose; F, plasma insulin; G, Acute (120min) blood glucose lowering by AZD1656 (drug tolerance test); H, blood triglycerides (TAGs); I, liver triglycerides (TAGs); J, liver mRNA after 4-weeks; K, liver mRNA after 8 weeks; L, liver glucokinase activity. Means ± SEM for n= (10-12, E-H) or n=6 (I-L).